Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study
Giacomo Caldarola, Andrea Chiricozzi, Matteo Megna, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 4, pp. 365-370
Closed Access | Times Cited: 9

Showing 9 citing articles:

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Sarah E. Thomas, Liana Barenbrug, Gerjon Hannink, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 565-578
Open Access | Times Cited: 14
Emerging strategies for nanomedicine in autoimmunity
Ajay S. Thatte, Margaret M. Billingsley, Drew Weissman, et al.
Advanced Drug Delivery Reviews (2024) Vol. 207, pp. 115194-115194
Closed Access | Times Cited: 10
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 10
Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years
Luca Mastorino, Paolo Dapavo, Lorenza Burzi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 3, pp. 568-575
Open Access | Times Cited: 10
Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study
Zheng Zhao, Zhanglei Mu, Yan Zhao, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113474-113474
Closed Access | Times Cited: 3
Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 4
Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study
Elisa Bellis, Piero Ruscitti, Denise Donzella, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 716-716
Open Access | Times Cited: 1
Ixekizumab for the Treatment of Moderate-To-Severe Plaque Psoriasis: The First Septennium
Elena Carmona‐Rocha, L. Puig
Immunotherapy (2023) Vol. 15, Iss. 15, pp. 1209-1225
Closed Access | Times Cited: 1
Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
Massimo Travaglini, Julia‐Tatjana Maul, Christian Kors, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2971-2983
Open Access | Times Cited: 1
Page 1

Scroll to top